We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

CZR:NASDAQCaesars Entertainment, Inc. Analysis

Data as of 2026-06-18 - not real-time

$29.21

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

Caesars Entertainment (CZR) is trading at $29.21, just below its short‑term resistance of $29.58 and comfortably above the 20‑day SMA of $29.02, indicating a technically bullish stance. The 50‑day SMA ($28.06) also lies beneath the price, reinforcing a medium‑term uptrend, while the 200‑day SMA ($24.73) shows a long‑term bullish bias. Momentum indicators are mixed: RSI at 58.6 points to modest strength, yet the MACD histogram is negative and the signal line is labeled bearish, suggesting potential near‑term consolidation. Volatility is elevated at 33.3% over the past 30 days, but beta (0.95) implies the stock moves roughly in line with the market, mitigating systematic risk. Fundamentals reveal a forward P/E of 34.7, a price‑to‑book of 1.74, and a price‑to‑sales of 0.51, which together suggest the market is pricing significant growth expectations into a company that currently posts a -4.2% profit margin and a -10.7% ROE. The balance sheet is heavily leveraged, with a debt‑to‑equity ratio exceeding 700, and cash on hand covers only a fraction of total debt, heightening financial risk. Analyst sentiment is mixed: while the consensus recommendation remains a "Buy" with a 16.2% upside target, three major houses (CBRE, JP Morgan, Susquehanna) downgraded their outlook to neutral or hold on May 29, reflecting concerns over execution and leverage. A potential acquisition by Tilman Fertitta adds a catalyst that could unlock value, but also introduces execution uncertainty. Overall, the stock sits at a pivotal point where technical strength, high valuation, and financial fragility intersect, making the next few quarters critical for direction.
Given the extreme greed reading on the Fear & Greed Index (90.95) and the modest upside of ~9% relative to the current price, investors should weigh the upside against the substantial debt load and earnings volatility. The decreasing volume trend hints at waning short‑term enthusiasm, while the support level at $27.11 offers a floor that could limit downside if the market respects technical levels. In this context, a cautious stance—maintaining exposure while monitoring earnings, debt reduction progress, and acquisition developments—is prudent.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Price hovering just below resistance with bullish SMA alignment
  • Mixed MACD signal and decreasing volume indicating possible consolidation
  • Recent downgrades from major analysts adding short‑term uncertainty

Medium Term

1–3 years
Positive
Model confidence: 7/10

Key Factors

  • Projected upside of ~9% and forward PE suggesting growth expectations
  • Potential acquisition by Tilman Fertitta as a value catalyst
  • Technical trend remaining bullish across 20‑, 50‑, and 200‑day SMAs

Long Term

> 3 years
Neutral
Model confidence: 6/10

Key Factors

  • High debt‑to‑equity ratio and negative profitability creating financial strain
  • Consumer‑cyclical exposure and regulatory environment adding sector risk
  • Long‑term price support at $27.11 and modest upside limiting upside potential

Key Metrics & Analysis

Financial Health

Revenue Growth2.70%
Profit Margin-4.20%
P/E Ratio34.7
ROE-10.72%
ROA4.08%
Debt/Equity722.66
P/B Ratio1.7
Op. Cash Flow$1.3B
Free Cash Flow$752.6M

Technical Analysis

TrendBullish
RSI58.6
Support$27.11
Resistance$29.58
MA 20$29.02
MA 50$28.06
MA 200$24.73
MACDBearish
VolumeDecreasing
Fear & Greed Index90.95

Valuation

Target Price$31.87
Upside/Downside9.10%
GradeOvervalued
TypeBlend

Risk Assessment

Beta0.95
Volatility33.31%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.